OncoMed Pharmaceuticals is a biotechnology company dedicated to improving cancer treatment by developing monoclonal antibodies and other agents that target the biologic pathways critical to tumor initiating cells, also known as “cancer stem cells”. OncoMed is leveraging our understanding of these tumor initiating cells to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer.
Website: www.oncomed.com